522 related articles for article (PubMed ID: 33679728)
21. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG).
Tang F; Xu Y; Chen H; Xu L; Zhang X; Wang Y; Liu Q; Wu D; Huang X
Sci China Life Sci; 2020 Apr; 63(4):571-581. PubMed ID: 31420852
[TBL] [Abstract][Full Text] [Related]
22. Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation.
Nomura S; Ishii K; Fujita S; Nakaya A; Satake A; Ito T
Transpl Immunol; 2017 Aug; 43-44():27-32. PubMed ID: 28687251
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study.
Heberton MM; Tripathi S; Slade M; Trinkaus K; Romee R; Anadkat M
J Am Acad Dermatol; 2020 Dec; 83(6):1654-1658. PubMed ID: 31689447
[TBL] [Abstract][Full Text] [Related]
24. Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia.
Konuma T; Matsuda K; Shimomura Y; Tanoue S; Sugita J; Inamoto Y; Hirayama M; Ara T; Nakamae H; Ota S; Maruyama Y; Eto T; Uchida N; Tanaka M; Ishiwata K; Koi S; Takahashi S; Ozawa Y; Onizuka M; Kanda Y; Kimura T; Ichinohe T; Atsuta Y; Kanda J; Yanada M
Transplant Cell Ther; 2023 Jun; 29(6):365.e1-365.e11. PubMed ID: 36889507
[TBL] [Abstract][Full Text] [Related]
25. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft
Li T; He Q; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Ding X; Tong Y; Wan L; Song X
Cell Transplant; 2022; 31():9636897221139103. PubMed ID: 36433646
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
27. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children.
Medina D; Estacio M; Rosales M; Manzi E
Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):208-213. PubMed ID: 32224144
[TBL] [Abstract][Full Text] [Related]
28. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.
Li X; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Tong Y; Dong B; Wan L; Song X
Front Immunol; 2023; 14():1252879. PubMed ID: 37954615
[TBL] [Abstract][Full Text] [Related]
29. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide.
Muñiz P; Kwon M; Carbonell D; Chicano M; Bailén R; Oarbeascoa G; Suárez-González J; Andrés-Zayas C; Menárguez J; Dorado N; Gómez-Centurión I; Anguita J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2021; 12():642087. PubMed ID: 33841425
[TBL] [Abstract][Full Text] [Related]
30. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
31. Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.
Solh MM; Baron J; Zhang X; Bashey A; Morris LE; Holland HK; Solomon SR
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2082-2088. PubMed ID: 32745575
[TBL] [Abstract][Full Text] [Related]
32. [A preliminary study on clinical diagnostic value of plasma elafin in skin acute graft-versus-host disease].
Luo CW; Weng JY; Wu SJ; Lu ZS; Guo R; Du X
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):922-5. PubMed ID: 23363749
[TBL] [Abstract][Full Text] [Related]
33. [Clinical study of the efficacies of ruxolitinib plus low-dose PTCY for acute GVHD prevention after haploidentical transplantation in malignant hematological diseases].
Li XP; Li Y; Liu L; Yuan ZT; Wang YC; Dong YC; Zhang DS; Feng J; Chen YN; Wang SB
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):128-133. PubMed ID: 38604788
[No Abstract] [Full Text] [Related]
34. Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies.
Alfaro Moya T; Salas MQ; Santos Carreira A; Atenafu EG; Law AD; Lam W; Pasic I; Kim DDH; Michelis FV; Novitzky Basso I; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Viswabandya A
Bone Marrow Transplant; 2024 Apr; 59(4):534-540. PubMed ID: 38317015
[TBL] [Abstract][Full Text] [Related]
35. Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide.
Kurita N; Sakamoto T; Kato T; Kusakabe M; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
Ann Hematol; 2021 May; 100(5):1295-1301. PubMed ID: 33580280
[TBL] [Abstract][Full Text] [Related]
36. High plasma IL-6 levels following haploidentical allogeneic hematopoietic stem cell transplantation post-transplant cyclophosphamide as predictor of early death and worse outcome.
Farias MG; de Mello Vicente B; Habigzang M; Hirakata VN; de Oliveira da Silva P; Paz AA; Daudt LE
Transpl Immunol; 2022 Apr; 71():101543. PubMed ID: 35093504
[TBL] [Abstract][Full Text] [Related]
37. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
[TBL] [Abstract][Full Text] [Related]
38. Failure to Prevent Severe Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Chronic Granulomatous Disease.
Parta M; Hilligoss D; Kelly C; Kwatemaa N; Theobald N; Zerbe CS; Holland SM; Malech HL; Kang EM
J Clin Immunol; 2020 May; 40(4):619-624. PubMed ID: 32314173
[TBL] [Abstract][Full Text] [Related]
39. Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bykova TA; Chukhlovin AB; Pevtcov DE; Bondarenko SN; Afanasyev BV
Eur J Haematol; 2018 May; 100(5):395-402. PubMed ID: 29360184
[TBL] [Abstract][Full Text] [Related]
40. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide.
Solán L; Landete E; Bailén R; Dorado N; Oarbeascoa G; Anguita J; Díez-Martín JL; Kwon M
Hematol Oncol; 2020 Oct; 38(4):597-603. PubMed ID: 32592410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
